Fadolmidine

Fadolmidine (development code MPV-2426) is an experimental α₂ adrenergic receptor agonist that has been investigated as a spinal analgesic. It was developed with the aim of providing antinociceptive effects with reduced systemic side effects compared to other α₂ agonists.^[1]

Fadolmidine

Clinical data
Other names	MPV-2426; Radolmidine
ATC code	none
Legal status
Legal status	Not approved
Identifiers
IUPAC name N-[4-(acridin-9-ylamino)phenyl]-2-phenylacetamide
CAS Number	189353-32-0
PubChem CID	44336989
ChemSpider	23192404
ChEMBL	ChEMBL325311
Chemical and physical data
Formula	C13H14N2O
Molar mass	214.268 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=CC=C(C=C1)CC(=O)NC2=CC=C(C=C2)NC3=C4C=CC=CC4=NC5=CC=CC=C53
InChI InChI=1S/C27H21N3O/c31-26(18-19-8-2-1-3-9-19)28-20-14-16-21(17-15-20)29-27-22-10-4-6-12-24(22)30-25-13-7-5-11-23(25)27/h1-17H,18H2,(H,28,31)(H,29,30) Key:KFOZTMBTDOTLMI-UHFFFAOYSA-N

Pharmacology

Fadolmidine acts as a selective α₂ adrenergic receptor agonist, a receptor class associated with modulation of nociceptive signalling. A 2004 review described preclinical evidence of spinal antinociceptive effects in laboratory models and suggested a reduced propensity for sedation compared with systemic α₂ agonists.^[1]

Development

The compound was developed under the code MPV-2426. As of 2025, it has no approved medical indication and has not advanced to late-stage clinical development.^[2]

Chemistry

Fadolmidine is an imidazole-derived compound structurally related to other α₂ agonists such as medetomidine and dexmedetomidine.^[1]